Last reviewed 2026-05-26 · How we verify

Penspek (FENBENICILLIN)

Phase 2 active Small molecule ✓ Verified May 2026

Penspek (generic name: FENBENICILLIN) is a fenbenicillin drug. It is currently in Phase 2 development.

Fenbenicillin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Penspek is a small molecule modality. It is also known by the synonyms (ALPHA-PHENOXYBENZYL)PENICILLIN, FENBENICILINA, FENBENICILLIN, and FENBENICILLINE.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENBENICILLIN
Drug class	fenbenicillin
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like buildings, and the bacteria are like construction workers. Fenbenicillin stops the construction workers from building new walls, causing the bacteria to die. This is a simplified explanation of how fenbenicillin works at a cellular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Penspek CI brief — competitive landscape report
Penspek updates RSS · CI watch RSS

Frequently asked questions about Penspek

What is Penspek?

Penspek (FENBENICILLIN) is a fenbenicillin drug.

How does Penspek work?

Fenbenicillin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

What is the generic name of Penspek?

FENBENICILLIN is the generic (nonproprietary) name of Penspek.

What drug class is Penspek in?

Penspek belongs to the fenbenicillin class. See all fenbenicillin drugs at /class/fenbenicillin.

What development phase is Penspek in?

Penspek is in Phase 2.

Drug class: All fenbenicillin drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing